Praziquantel compounds for treating diseases due to Sarcocystis, Neospora, Toxoplasma and Isospora

Abstract

Disclosed herein are compositions and methods of treating therapeutically, or metaphylactically infected mammals susceptible to, or infected mammals suffering from parasitic neurologic or abortigenic diseases such as Sarcocystis, Neosporosis or Toxoplasmosis or Isosporosis that are treatable with a praziquantel compound by administering thereto a composition containing a pharmaceutically effective amount of praziquantel or derivative thereof, including metaphylactic and single high dose treatment regimens.

What is claimed is:  
     
         1 . A praziquantel composition for treating a diseased mammal suffering from a parasitic neurologic or abortigenic disease that is susceptible to being treated with a praziquantel compound, comprising a pharmaceutically effective amount of praziquantel or a derivative thereof and a pharmaceutically acceptable carrier.  
     
     
         2 . The composition  claim 1  wherein the disease is caused by a coccidia.  
     
     
         3 . The composition of  claim 2  wherein the coccidia is a member of the group consisting of  Sarcocystis spp, Neospora spp, Toxoplasma spp  and  Isospora spp.    
     
     
         4 . The composition of  claim 3  wherein the  Sarcocystis spp  is  Sarcocystis neurona , the  Neospora spp  is  Neospora caninum  or  Neospora hugesi,  the  Toxoplasma spp  is  Toxoplasma gondii  and the  Isospora spp  is  Isospora suis.    
     
     
         5 . The composition of  claim 4  wherein the  Sarcocystis neurona  is the causative agent of Equine Protozoal Myeloencephalyitis.  
     
     
         6 . The composition of  claim 4  wherein the  Neospora caninum  is the causative agent of bovine or canine Neosporosis.  
     
     
         7 . The composition of  claim 4  wherein the  Neospora hugesi  is the causative agent of Equine Protozoal Myeloencephalyitis.  
     
     
         8 . The composition of  claim 4  wherein the  Toxoplasma gondii  is the causative agent of Toxoplasma-associated abortion in mammals.  
     
     
         9 . A praziquantel composition for treating a diseased mammal suffering from a parasitic neurologic or abortigenic disease that is susceptible to being treated with a praziquantel compound, comprising a neurologically-effective or placentally-effective amount of praziquantel or a derivative thereof and a pharmaceutically acceptable carrier.  
     
     
         10 . A method of therapeutically treating a diseased mammal suffering from a parasitic neurologic or abortigenic disease that is susceptible to being treated with a praziquantel compound, comprising administering to the mammal a composition of a pharmaceutically effective amount of praziquantel or a derivative thereof and a pharmaceutically acceptable carrier.  
     
     
         11 . The method of  claim 10  wherein the disease is caused by a coccidia.  
     
     
         12 . The method of  claim 11  wherein the coccidia is a member of the group consisting of  Sarcocystis spp, Neospora spp, Toxoplasma spp  and  Isospora spp.    
     
     
         13 . The method of  claim 12  wherein the  Sarcocystis spp  is  Sarcocystis neurona , the  Neospora spp  is  Neospora caninum  or  Neospora hugesi,  the  Toxoplasma spp  is  Toxoplasma gondii  and the  Isospora spp  is  Isospora suis.    
     
     
         14 . The method of  claim 13  wherein the  Sarcocystis neurona  is the causative agent of Equine Protozoal Myeloencephalyitis.  
     
     
         15 . The method of  claim 12  wherein the  Neospora caninum  is the causative agent of bovine or canine Neosporosis.  
     
     
         16 . The method of  claim 12  wherein the  Neospora hugesi  is the causative agent of Equine Protozoal Myeloencephalyitis.  
     
     
         17 . The method of  claim 12  wherein the  Toxoplasma gondii  is the causative agent of Toxoplasma-associated abortion in mammals.  
     
     
         18 . A method for treating a diseased mammal suffering from a parasitic neurologic or abortigenic disease that is susceptible to being treated with a praziquantel compound, comprising administering to the mammal a neurologically-effective or placentally-effective amount of praziquantel or a derivative thereof and a pharmaceutically acceptable carrier.  
     
     
         19 . The method of metaphylactically treating mammals infected with a parasite that is a causative agent for a neurologic or abortigenic disease that is susceptible to being treated with a praziquantel compound, comprising administering thereto a methaphylactically-effective regimen of a composition of a pharmaceutically effective amount of the praziquantel compound or a derivative thereof and a pharmaceutically-acceptable carrier.  
     
     
         20 . The method of  claim 10  wherein the composition is administered in two or more intermittent doses.  
     
     
         21 . The method of  claim 10  wherein the composition is administered in a dose of about 1.0 and 100 mg/Kg.  
     
     
         22 . The method of  claim 21  wherein the composition is administered in a dose of about 1.0 and 50 mg/Kg.  
     
     
         23 . The method of  claim 10  wherein the composition is administered in a single high dose of greater than 50 mg/Kg.